ELDN — Eledon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $186.90m
- $137.16m
Eledon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million
Eledon Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Eledon Pharmaceuticals Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Eledon Pharmaceuticals Announces Pricing Of $85 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants
Brief: Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart As Part Of An Immunosuppression Regimen Following Islet Transplantation In Investigator-Initiated Trial At Uchicago Medicine
Brief: Eledon Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Brief: Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Brief: Eledon Pharmaceuticals Inc Files For Resale Of Up To 21 Mln Shares Of Common Stock Offered By Selling Stockholders
Eledon Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Eledon Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eledon Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Eledon Pharmaceuticals Announces 12Th Participant Enrolled In Phase 2 Bestow Trial Evaluating Tegoprubart For The Prevention Of Organ Rejection
US surgeons perform first pig-to-human kidney transplant (updated)
Brief: Eledon Pharmaceuticals Highlights Recent Business Milestones And Provides 2024 Outlook
Brief: Eledon Pharmaceuticals Q3 basic EPS USD -0.35